RT Conference Proceedings
T1 ATEZOLIZUMAB PLUS VEMURAFENIB AND COBIMETINIB PROVIDES FAVORABLE SURVIVAL OUTCOMES IN PATIENTS WITH HIGH TUMOR MUTATION BURDEN AND PROINFLAMMATORY GENE SIGNATURE IN THE PHASE 3 IMSPIRE150 STUDY
A1 Lewis, Karl
A1 Ascierto, Paolo
A1 Robert, Caroline
A1 Munhoz, Rodrigo
A1 Liszkay, Gabriella
A1 De La Cruz Marino, Luis
A1 Olah, Judit
A1 Queirolo, Paola
A1 Mackiewicz, Jacek
A1 Shah, Kalpit
A1 Forbes, Harper
A1 Hertig, Christian
A1 Yan, Yibing
A1 Gutzmer, Ralf
A1 McArthur, Grant
PB Bmj publishing group
YR 2020
FD 2020-11-01
LK https://hdl.handle.net/10668/27584
UL https://hdl.handle.net/10668/27584
LA en
DS RISalud
RD Apr 7, 2025